|
Context Therapeutics Inc. (CNTX) Évaluation DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Context Therapeutics Inc. (CNTX) Bundle
Explorez l'avenir financier de Context Therapeutics Inc. (CNTX) avec notre calculatrice DCF conviviale! Entrez vos projections pour la croissance, les marges bénéficiaires et les dépenses pour calculer la valeur intrinsèque de Context Therapeutics Inc. (CNTX) et améliorez votre stratégie d'investissement.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | .0 | .0 | -10.5 | -14.8 | -25.1 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | 5.4 | 2.6 | -3.1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -5.4 | -2.6 | -7.4 | -14.8 | -25.1 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | .2 | .3 | 49.6 | 35.5 | 14.4 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 2.1 | 2.7 | 1.8 | .9 | 2.4 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | -.3 | -.5 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -6.3 | -2.6 | -5.3 | -14.3 | -25.1 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 1.1 | .6 | -9.5 | -15.7 | -23.6 | -2.4 | .0 | .0 | .0 | .0 |
| WACC, % | 13.75 | 13.75 | 13.75 | 13.75 | 13.75 | 13.75 | 13.75 | 13.75 | 13.75 | 13.75 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -2 | |||||||||
| Net Debt | -14 | |||||||||
| Equity Value | 12 | |||||||||
| Diluted Shares Outstanding, MM | 16 | |||||||||
| Equity Value Per Share | 0.77 |
What You Will Get
- Real CNTX Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Explore various scenarios to assess Context Therapeutics' future performance.
- User-Friendly Design: Designed for industry professionals but easy for newcomers to navigate.
Key Features
- Comprehensive Financial Data: Gain access to precise historical performance and future forecasts for Context Therapeutics Inc. (CNTX).
- Adjustable Forecast Parameters: Modify highlighted cells for key variables such as WACC, growth rates, and profit margins.
- Real-Time Calculations: Instant updates for DCF, Net Present Value (NPV), and cash flow assessments.
- User-Friendly Dashboard: Intuitive charts and summaries to help you interpret your valuation outcomes.
- Designed for All Levels: A straightforward layout tailored for investors, CFOs, and consultants alike.
How It Works
- Step 1: Download the prebuilt Excel template containing Context Therapeutics Inc.'s (CNTX) data.
- Step 2: Review the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see the recalculated results, including Context Therapeutics Inc.'s (CNTX) intrinsic value.
- Step 5: Utilize the outputs to make informed investment decisions or create detailed reports.
Why Choose This Calculator for Context Therapeutics Inc. (CNTX)?
- Designed for Industry Experts: A specialized tool utilized by healthcare analysts, CFOs, and biotech consultants.
- Comprehensive Data: Context Therapeutics' historical and projected financials are preloaded for precise analysis.
- Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions to explore potential outcomes.
- Insightful Outputs: Automatically computes intrinsic value, NPV, and other essential metrics.
- User-Friendly Interface: Clear, step-by-step guidance helps you navigate through the calculations.
Who Should Use This Product?
- Healthcare Investors: Develop comprehensive valuation models for analyzing Context Therapeutics Inc. (CNTX) investments.
- Biotech Research Teams: Evaluate valuation scenarios to inform strategic decisions within the company.
- Financial Consultants: Deliver precise valuation insights for clients interested in Context Therapeutics Inc. (CNTX).
- Students and Instructors: Utilize real-world data to practice and teach financial modeling in the biotech sector.
- Pharmaceutical Enthusiasts: Gain an understanding of how biotech firms like Context Therapeutics Inc. (CNTX) are valued in the market.
What the Template Contains
- Preloaded CNTX Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.